Breast cancer patients ‘denied life-extending drugs because of unfair system'
Breast Cancer Now has demanded 'immediate action' from Health Secretary Wes Streeting, urging him to scrap spending restraints.
It is also calling for the NHS spending watchdog the National Institute for Health and Care Excellence (Nice) to lower the bar for what it classes as a very severe health condition.
Nice's severity modifier, introduced in 2022, gives treatment for more severe illnesses more weight, meaning the health benefits of certain drugs are valued more highly and more likely to be recommended for NHS use.
According to Nice, the process raises the threshold for what it considers to be a cost-effective treatment, meaning it can give more expensive drugs the green light.
However, a new report from Breast Cancer Now claims the system means women with incurable breast cancer with months to live may be told their condition does not qualify for the most severe rating.
The call comes after it emerged that the life-extending drug Enhertu will not be made available for women with incurable breast cancer on the NHS in England and Wales.
In November, Nice said talks with manufacturers AstraZeneca and Daiichi Sankyo over the price of the medication had broken down for the third time with no agreement.
Claire Rowney, chief executive at Breast Cancer Now, said: 'The terrifying reality is that unless urgent action is taken thousands of women in the UK with incurable secondary breast cancer could be denied access to vital life-extending treatments because of an unfair system.
'We're talking about patients missing out on access to cutting-edge, effective treatments that could give them more time to be there for special moments such as birthdays or seeing their children or grandchildren start school.
'Treatments, such as Enhertu, that patients in other countries, including Scotland, can access, giving them the chance to live longer.
'Women with secondary breast cancer tell us they feel their lives are being deprioritised by the changes to the system.
'We will not stand by and witness more drugs being rejected or not taken forward, when the devastating cost is thousands more people with secondary breast cancer across England, Wales and Northern Ireland having their lives cut short.'
Paula Van Santen, 50, was diagnosed with secondary breast cancer in July 2022, two months after her diagnosis of primary breast cancer.
The mother-of-three, from Banbury in Oxfordshire, said: 'Secondary breast cancer has changed the lives of both myself and my family beyond belief. Coming to terms with my diagnosis is the hardest part because I've had to grieve for the life I had, but also the life that I'm not going to have.
'If a new drug can give me another six months, if it gives me another year, it's worth it.
'It could allow me to see my daughter get to 21, see my children get married or meet grandchildren. Just to have a picture with a grandchild so they would know that I existed would be so precious. That's what this could give.'
Ms Rowney called for 'change' and said Mr Streeting should scrap 'opportunity-cost neutral' restraints.
Opportunity cost neutrality in the Nice severity modifier aims to ensure the new system does not require more or less overall NHS funding than the old one.
According to the Breast Cancer Now report, this is 'at the root of the issues with the modifier'.
It added: 'It pits end-of-life cancer treatments against other severe conditions like cystic fibrosis in a way that's reductive and unfair to patients. And, ultimately, it creates barriers to the approval of drugs for advanced cancers.'
Ms Rowney said: 'The system for deciding whether drugs are approved for use on the NHS must change now.
'We're calling for immediate action from Wes Streeting, Secretary of State for Health and Social Care, to urgently scrap 'opportunity-cost neutral' restraints and for Nice to lower the bar for what it defines as 'a severe condition'. And we stand ready to work with them.'
Dr Samantha Roberts, chief executive of Nice, welcomed the report from Breast Cancer Now, saying: 'The independent analysis we commissioned recently showed the new severity weighting is working as intended and expected.
'It is able to be applied more widely – for example to treatments for cystic fibrosis, hepatitis D and Duchenne muscular dystrophy – and has contributed to an increase in positive decisions for cancer medicines and non-cancer medicines.
'And other breast cancer treatments have been recommended since we introduced the severity modifier – including for advanced breast cancer.
'We remain deeply disappointed that we were unable to recommend Enhertu for HER2-low advanced breast cancer. We know this was devastating to all those hoping for a different answer.
'It remains the only breast cancer treatment we have been unable to recommend in seven years.'
A Department of Health and Social Care spokesperson said the upcoming 10-year health plan will 'transform the NHS and improve care for those facing cancer'.
'This includes rolling out DIY screening kits for cervical cancer, more radiotherapy machines in every region and opening more Community Diagnostic Centres closer to where people live,' they added.
'We know how disappointing it is to many families that the manufacturers of Enhertu are unwilling to sell this life-extending treatment to the NHS at a fair and reasonable price. Our door remains open to supporting the introduction of medicines at a cost-effective price.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
HRT ‘can raise breast cancer risk' in younger women
Hormone replacement therapy can raise the risk of breast cancer in some younger women, a Lancet study suggests. An international team of researchers found the treatment was not linked to young onset breast cancer overall. But oestrogen plus progestin therapy appears to increase breast cancer risk by 10 per cent. Meanwhile, oestrogen hormone therapy use appeared to decrease breast cancer risk by 14 per cent. Hormone replacement therapy is a treatment used to help menopause symptoms. There are different types of HRT, which is used to treat menopause symptoms, available. They contain different hormones: some are oestrogen products; others contain progestogen and other types have both. These medicines can be taken or used in different ways and work by replacing the hormones oestrogen and progesterone, which can fall to lower levels as women approach the menopause. Most studies examining links between hormone therapy and breast cancer risk have been explored in older women. Previous work, which has focused on women who have already been through the menopause, suggest that oestrogen plus progestin hormone therapy is a risk factor for breast cancer. The researchers, led by academics from the National Institute of Environmental Health Sciences in the US, wanted to explore the risks among younger women on hormone therapy – who may take these drugs after gynaecological surgery or during perimenopause. The new meta-analysis published in the journal, Lancet Oncology, examined data drawn from previous studies of 459,476 women aged 16 to 54 years old. Some two per cent of this group (8,455) developed young-onset breast cancer, which means the disease was diagnosed before they were 55 years old. And 15 per cent of women involved in the study reported using hormone therapy, with oestrogen plus progestin hormone therapy and oestrogen being the most common types. 'Although the strength of these associations might vary by age at first use, duration of use, gynaecological surgery status, and other factors, unopposed oestrogen hormone therapy use appears to decrease breast cancer risk and oestrogen plus progestin therapy appears to increase breast cancer risk,' the authors wrote. 'The findings can be used to augment clinical recommendations for hormone therapy use in young women, for whom guidance was previously scarce.' Dr Kotryna Temcinaite, the head of research communications at Breast Cancer Now, said: 'These results are largely in line with what we already know about taking HRT for menopausal symptoms and its effects on breast cancer risk – for most people, the risk of developing breast cancer because of taking HRT is small and is outweighed by the benefits. 'Taking HRT is a very personal decision and, as such, it's vital that everyone has the information they need on the benefits and risks, discusses them with their GP or specialist team and is supported to make the choice that's right for them.' Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more.
Yahoo
25 minutes ago
- Yahoo
WHO pushes for 50% price rise through taxes on sugar, alcohol and tobacco
By Jennifer Rigby LONDON (Reuters) -The World Health Organization is pushing countries to raise the prices of sugary drinks, alcohol and tobacco by 50% over the next 10 years through taxation, its strongest backing yet for so-called "sin taxes" to help tackle chronic public health problems and boost government health budgets. The United Nations health agency said the move would help cut consumption of the products, which contribute to diseases like diabetes and some cancers, as well as raising money at a time when development aid is shrinking and public debt rising. "Health taxes are one of the most efficient tools we have," said Jeremy Farrar, WHO assistant-director general of health promotion and disease prevention and control. "It's time to act." The WHO launched the push, which it is called "3 by 35" at the UN Finance for Development conference in Seville. WHO said that its tax initiative could raise $1 trillion by 2035 based on evidence from health taxes in countries such as Colombia and South Africa. The WHO has backed tobacco taxes and price rises for decades, and has called for taxes on alcohol and sugary drinks in recent years, but this is the first time it has suggested a target price rise for all three products. WHO Director-General Dr Tedros Adhanom Ghebreyesus told the conference that the taxes could help governments "adjust to the new reality" and bolster their own health systems with the money raised. As an example, it would mean a government in a middle-income country raising taxes on the product to push the price up from $4 today to $10 by 2035, taking into account inflation, said WHO health economist Guillermo Sandoval. Nearly 140 countries had already raised tobacco taxes and therefore prices by over 50% on average between 2012 and 2022, the WHO added. Sandoval said the WHO was also considering broader taxation recommendations, including on ultra-processed food, after the agency finalises its definition of that type of food in the coming months. But he added that the agency expected pushback from the industries involved. The initiative is also backed by Bloomberg Philanthropies, the World Bank and the Organization for Economic Co-operation and Development (OECD), and involves support for countries who want to take action. Sign in to access your portfolio
Yahoo
34 minutes ago
- Yahoo
Scientists Are Trying to Rebuild Humanity From Raw Genetic Code
"Hearst Magazines and Yahoo may earn commission or revenue on some items through these links." Here's what you'll learn when you read this story: For decades, scientists have been building synthetic versions of viruses, bacteria, and yeast, but now U.K. scientists are setting their sights on the human genome. Building a synthetic genome would be much different than gene editing, which contains smaller edits to one's own genome. While a synthetic human genome could dramatically improve our ability to manage our health, it could also be a deadly weapon if used for nefarious purposes. The ethical duality of scientific discovery is nothing new. The most dramatic example is, of course, splitting the atom, which delivered a promising new energy source as well as weapons of mass destruction. A more recent example—the internet—was an unprecedented way to access the sum total of human knowledge, and it also became an insidious vector of mass misinformation. Now scientists are embarking on a new scientific journey, one that could bring unimaginable benefits for human health while also providing the tools for immense destruction. We're going to synthesize the human genome. Over the next five years, the Synthetic Human Genome Project (SynHG), funded by the world's largest medical charity Wellcome Trust (which was also a partner of the Human Genome Project completed in 2003), will work with scientists from Cambridge, Kent, Manchester, Oxford, and Imperial College London to build the foundational tools necessary to rebuild the human genome from scratch. This is different than gene editing, which typically involves much smaller changes to an organism's original DNA. 'With recent technological advances, the SynHG project is at the forefront of one of the most exciting areas of scientific research,' Wellcome's Michael Dunn said in a press statement. 'Through creating the necessary tools and methods to synthesize a human genome, we will answer questions about our health and disease that we cannot even anticipate yet, in turn transforming our understanding of life and wellbeing.' In an interview with the BBC, Julian Sale, a member of the Molecular Biology in Cambridge who is part of the study, said that a synthetic human genome could improve the lives of humans as they age. This focus on healthspan—improving the quality of life for the years we do have—over lifespan is something medical professionals have been urging for years, and a synthetic human genome could address a wide variety of maladies that impact our quality of life in old age. And then, there's the other side of the scientific coin. While a synthetic genome could help generate disease-resistant cells or repair damaged organs or the immune system in general, the technology could also be used as a highly efficient biological weapon if it fell into the wrong hands. That's why SynHG will also develop social science programs that will examine the technology's ethical, legal, and social implications. 'The genie is out of the bottle,' Edinburgh University genetic scientist Bill Earnshaw told BBC News. 'We could have a set of restrictions now, but if an organization who has access to appropriate machinery decided to start synthesising anything, I don't think we could stop them.' When it comes to synthetic biology, the genie has actually been out of that proverbial bottle for a while now. In 2002, scientists in the U.S. first synthesized a viral genome, and since then, scientists have increased genomic complexity by synthesizing a bacterium in 2008 and a yeast organism in 2017. Of course, the human genome is leagues beyond these simple synthetic reconstructions, which is why the project scientists estimate that it could take decades to complete. Hopefully that provides enough time for humanity to fully grapple with the implications of such a breakthrough and ensure that we don't accidentally create yet another weapon of mass destruction. You Might Also Like The Do's and Don'ts of Using Painter's Tape The Best Portable BBQ Grills for Cooking Anywhere Can a Smart Watch Prolong Your Life?
